Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a preeminent global medical technology company with a significant presence in the wearable injectors market. The company develops and provides advanced solutions across healthcare, including innovative drug delivery systems designed for patient self-administration. In the wearable injector space, BD introduced the BD Libertas Wearable Injector, a sophisticated, prefilled device engineered for the subcutaneous delivery of high-viscosity biologics. This system accommodates drug volumes in 2 to 5 mL and 5 to 10 mL configurations, which is crucial for modern complex therapies. A key feature of the Libertas injector is its entirely mechanical, spring-driven power module, which eliminates the need for batteries and associated heavy metal disposal issues. The device is designed with a simple “peel, stick, and click” mechanism, ensuring ease of use and maximum patient convenience by removing the need for end-user filling or assembly. This patient-centric design, validated by extensive clinical studies, strengthens BD’s position as a leader committed to enhancing the quality of life and adherence for patients managing chronic conditions at home.
Latest Market Research Report on Wearable Injectors Download PDF Brochure Now
Medtronic
Medtronic plc is a global medical technology and services company that stands as a leading player in the wearable injectors market, primarily through its focus on managing chronic diseases, particularly diabetes. The company’s Connected Care segment develops integrated patient monitoring and drug delivery platforms that bridge the hospital and home care environments. Medtronic’s flagship contribution to the wearable injector space is the MiniMed 780G insulin pump system, an advanced solution offering automated insulin delivery based on continuous glucose monitoring (CGM). This system is highly regarded for its performance in preventing highs and lows in glucose management. Furthermore, Medtronic expanded its portfolio with the strategic acquisition of EOFlow Co., Ltd. in 2023, integrating the EOPatch—a tubeless, wearable, and disposable insulin delivery system. By continuously innovating and acquiring complementary technologies, Medtronic enhances its range of miniaturized smart wearable systems, integrating digital health and remote monitoring to offer precise, patient-friendly solutions that improve clinical outcomes and care efficiency for individuals with diabetes.
Insulet Corporation
Insulet Corporation is a market leader exclusively focused on simplifying life for people with insulin-requiring diabetes through its innovative, tubeless wearable technology. The company’s core offering, the Omnipod Insulin Management System, is a revolutionary tubeless, waterproof patch pump that adheres directly to the body and provides continuous insulin delivery for up to three days, eliminating the burden of multiple daily injections. Insulet’s most advanced product, the Omnipod 5 Automated Insulin Delivery (AID) System, represents a significant step in the wearable injectors market. The Omnipod 5 integrates with continuous glucose monitors (CGMs) to create a closed-loop system that automatically adjusts and delivers insulin based on real-time glucose readings, successfully improving time in range for users. By combining simplicity, convenience, and sophisticated control into a small, wearable Pod, Insulet has made complex diabetes management more accessible, less intrusive, and significantly more flexible, positioning the company as the most prescribed AID system in the U.S. and a driving force in the personalized care movement.
Amgen Inc.
Amgen Inc. is one of the world’s leading biopharmaceutical companies, leveraging the wearable injector market by focusing on the drug-device combination to enhance patient care for its innovative human therapeutics. Amgen specializes in discovering, developing, and delivering medicines for serious illnesses and has strategically integrated wearable technology to facilitate the self-administration of its biologics. Its most notable product in this domain is the Neulasta Onpro system, an on-body wearable injector designed to administer Neulasta (pegfilgrastim) automatically to chemotherapy patients the day after their treatment. This hands-free, on-body drug delivery system allows patients to receive their medication at home, reducing the need for an extra trip to the clinic or hospital and improving therapy adherence. By utilizing advanced drug-device combinations, Amgen maintains a competitive edge, focusing on patient-centric innovation that makes the delivery of complex biologics safer, more convenient, and seamlessly integrated into the lives of patients with chronic and complex conditions.
Ypsomed Holding AG
Ypsomed Holding AG is a key Swiss-based developer and manufacturer of self-injection systems, holding a prominent position as a reliable partner for pharmaceutical and biotech companies in the wearable injectors sector. The company provides a comprehensive portfolio of self-care solutions, including on-body devices, autoinjectors, and pen injectors. Ypsomed’s flagship wearable injector platform is YpsoDose, a pre-filled, ready-to-use patch injector engineered for the subcutaneous delivery of large drug volumes up to 10 mL. Ypsomed focuses on creating customizable and modular platforms that support the development and delivery of high-volume biologics with user-friendly design. Their expertise in self-injection systems, strong Original Equipment Manufacturer (OEM) partnerships, and commitment to human factors engineering ensure that their devices are safe, intuitive, and align with the growing trend of home healthcare. This strategic focus on quality, customization, and user convenience reinforces Ypsomed’s role in driving forward the self-administration of complex therapies.
Enable Injections
Enable Injections is an innovative healthcare company dedicated to improving the patient treatment experience through the development and manufacturing of its proprietary wearable drug delivery platform, enFuse. The company has carved out a niche by specializing in systems that comfortably and conveniently deliver large volumes of medications, typically administered subcutaneously, outside of a clinical setting. The hands-free enFuse wearable technology is designed to simplify complex treatment regimens. It delivers the needed therapy through a simple injection under the skin, often replacing more invasive or inconvenient intravenous treatments. The platform is highly recognized for its novel technology and focus on patient comfort and psychological freedom, allowing patients to reclaim their passions and not dread taking medication. Through strategic partnerships with leading pharma companies, Enable is actively conducting clinical trials and planning commercial launches to integrate the enFuse system with various partnered therapies, further accelerating the shift towards self-administered, high-volume drug delivery.
Johnson & Johnson Services, Inc.
Johnson & Johnson Services, Inc. (J&J) is a global healthcare conglomerate and a significant participant in the wearable injectors market, committed to developing innovative delivery systems that improve patient convenience and compliance for long-term therapies. Operating through its diverse segments, J&J leverages its extensive pharmaceutical and medical device expertise to address the challenges associated with frequent injections for chronic conditions, such as autoimmune diseases and diabetes. The company’s work in wearable injectors is centered on creating sophisticated, user-friendly devices that facilitate the self-administration of treatment. By focusing on smart, connected technologies, J&J aims to enhance the overall patient experience and outcomes in the management of long-term conditions. Their strategic approach involves developing robust delivery platforms that seamlessly integrate into a patient’s daily life, thereby encouraging greater adherence to drug regimens and supporting the broader shift towards decentralized and home-based healthcare delivery.
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. is a leading provider of innovative, integrated containment and delivery solutions for injectable medicines, establishing itself as a key player in the wearable injectors ecosystem. The company specializes in creating proprietary platforms and collaborating with pharmaceutical partners to facilitate the safe and effective subcutaneous delivery of biologics and specialty drugs. West is recognized for its SmartDose drug delivery platform, an extension of its offerings that includes various wearable injectors capable of administering volumes up to 10 mL. These devices, utilizing motor-driven or spring-based mechanisms, are designed for patient convenience and dosing precision, aligning with the growing demand for self-administration in the home setting. By providing critical components, technological expertise, and comprehensive packaging and delivery systems, West ensures the integrity of the drug while enhancing the user experience, making it an essential partner for biopharmaceutical firms looking to bring their complex therapies to market via advanced wearable technology.
Gerresheimer AG
Gerresheimer AG is a global partner to the pharmaceutical and healthcare industry, contributing significantly to the wearable injectors market through its advanced drug delivery systems. The company specializes in manufacturing specialized products such as pharmaceutical packaging, drug delivery devices, and micro-injection molding. Gerresheimer’s key offering in the wearable sector is the Gx SensAir platform, an on-body, subcutaneous delivery system that originated from its acquisition of Sensile Medical. The Gx SensAir is a ready-to-use device capable of administering large volumes, up to 20 mL, of high-viscosity biologics. A crucial feature of this system is its flexibility to be tailored to specific drug viscosity, volume, and connectivity requirements, supporting patient self-administration at home. By providing comprehensive development and manufacturing services, from design to final production, Gerresheimer reinforces its position as a top-tier supplier, enabling pharmaceutical companies to deliver their complex therapies through reliable and customizable wearable devices.
Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a prominent medical device company specializing in diabetes technology, particularly in developing and commercializing wearable insulin pump systems which function as advanced, automated wearable injectors. The company is dedicated to integrating digital health, remote monitoring, and IoT technology into its products to simplify diabetes management. Tandem’s flagship products include the t:slim X2 pump and the sleek, tiny Tandem Mobi system. Both systems are powered by Control-IQ+ technology, a predictive algorithm that automatically adjusts and corrects insulin delivery to help prevent both high and low blood glucose levels. Tandem’s focus is on providing a connected care experience, offering continuous glucose monitoring integration and enabling control via a personal smartphone. This commitment to automation, user experience, and connectivity ensures that patients as young as age 2 can benefit from highly personalized, precise, and less burdensome insulin therapy, establishing Tandem as a major leader in the automated insulin delivery segment of the wearable injectors market.
Latest Market Research Report on Wearable Injectors Download PDF Brochure Now